DUBLIN – Investor interest in Polyneuron Pharmaceuticals AG's Antibody-Catch technology for selectively removing pathological auto-antibodies from the circulation was "very astonishing," CEO and co-founder Ruben Herrendorff told BioWorld. The result was a solid CHF22.5 million (US$22.6 million) series A round led by Sofinnova Partners and co-led by New Enterprise Associates (NEA), which will enable it to complete phase I development of its lead drug candidate, to prepare for a phase II trial and to progress several other earlier stage indications.